amikacin has been researched along with Cardiomegaly in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, W; Hu, C; Liao, HH; Tang, QZ; Wang, SS; Wei, WY; Yang, Z; Zhang, N | 1 |
| Hu, X; Li, T; Liu, J; Ou-Yang, Q; Wang, L; Xie, X | 1 |
2 other study(ies) available for amikacin and Cardiomegaly
| Article | Year |
|---|---|
AdipoRon, an adiponectin receptor agonist, attenuates cardiac remodeling induced by pressure overload.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Blood Pressure; Cardiomegaly; Cell Differentiation; Fibroblasts; Humans; Male; Mice, Inbred C57BL; Mice, Knockout; Piperidines; Rats, Sprague-Dawley; Receptors, Adiponectin; Transforming Growth Factor beta1; Ventricular Remodeling | 2018 |
AdipoRon prevents l-thyroxine or isoproterenol-induced cardiac hypertrophy through regulating the AMPK-related pathway.
Topics: AMP-Activated Protein Kinases; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Gene Expression; Isoproterenol; Male; Natriuretic Peptide, Brain; Organ Size; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Piperidines; Rats, Sprague-Dawley; Signal Transduction; Thyroxine | 2019 |